GlassScriptPhysician profile
Sasha D Plank
NPI 1164855110
$2,198.51
in general payments reported to CMS, 2019-2025
19 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $303 · 2023: $492 · 2024: $660 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $638.39 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $269.90 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $184.09 | 2021-2024 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $173.45 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $137.55 | 2024-2025 | |
| Pfizer INC. | $130.82 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.72 | 2023-2025 | Jardiance |
| Amgen INC. | $95.09 | 2021-2024 | Otezla, Repatha, Evenity |
| Supernus Pharmaceuticals, INC. | $77.61 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.59 | 2025 | Caplyta |
| Abbott Laboratories | $73.82 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $66.91 | 2021-2025 | |
| Adlon Therapeutics L.P. | $64.72 | 2021 | |
| Glaxosmithkline, LLC. | $40.44 | 2022-2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $15.46 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.83 | 2025 | |
| Esperion Therapeutics, INC. | $13.73 | 2023 | Nexletol |
| Ironshore Pharmaceuticals INC. | $13.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sasha Plank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.